ExelixisEXEL
About: Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Employees: 1,147
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
125% more call options, than puts
Call options by funds: $77.7M | Put options by funds: $34.5M
79% more first-time investments, than exits
New positions opened: 100 | Existing positions closed: 56
25% more repeat investments, than reductions
Existing positions increased: 212 | Existing positions reduced: 169
11% more funds holding in top 10
Funds holding in top 10: 9 [Q4 2024] → 10 (+1) [Q1 2025]
11% more capital invested
Capital invested by funds: $8.33B [Q4 2024] → $9.23B (+$907M) [Q1 2025]
7% more funds holding
Funds holding: 514 [Q4 2024] → 548 (+34) [Q1 2025]
1.88% more ownership
Funds ownership: 87.53% [Q4 2024] → 89.41% (+1.88%) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
HC Wainwright & Co. Robert Burns | 13%upside $47 | Buy Maintained | 12 Jun 2025 |
B of A Securities Jason Gerberry | 11%upside $46 | Neutral Maintained | 5 Jun 2025 |
Citigroup David Lebowitz | 35%upside $56 | Buy Maintained | 15 May 2025 |
Stifel Stephen Willey | 9%downside $38 | Hold Maintained | 14 May 2025 |
RBC Capital Gregory Renza | 4%downside $40 | Outperform Reiterated | 14 May 2025 |
Financial journalist opinion
Based on 23 articles about EXEL published over the past 30 days
